
Tgen Tech LLC Profile last edited on: 2/14/2020
CAGE: 844Z0
UEI: D9WMZ24BAKL5
Business Identifier: Proprietary medical device technology: augments cardiac tissues and grows with patient. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 06
County: Fulton
Congr. District: 06
County: Fulton
Public Profile
Headquartered in Georgia but having facilites also in Greenville SC., TGen Tech, LLC is a healthcare company having developed a patented. breakthrough technologies that is targeted at improving soft tissue healing. Current focus on cardiovascular applications. The firm is developing a differentiated Pulmonary Valved Conduit to improve the clinical outcomes of substitute conduit arteries in infants and children with Congenital Heart Defects (CHD). An estimated 2.5 million patients in the US have a CHD, which includes 40,000 newborns annually. Several thousand of these patients have a defect that requires the use of a non-native conduit artery, such as a bovine jugular vein (BJV), to replace structures that are congenitally absent or hypoplastic. TGen Tech uses patented decellularization and physical fixation technology for valved conduit devices to augment the already recognized qualities of BJV and several other cardiovascular applications, including heart valve repair and replacement devices.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $3,062,966 | |
Project Title: Pulmonary Valved Conduit Xenograft with Regeneration Potential | ||||
2020 | 1 | NIH | $327,779 | |
Project Title: Decellularized Xenograft Leaflet Patch for Pulmonary Valve Repair in Pediatric Patients |
Key People / Management
Ajay Houder -- Co-Founder and CEO
Naren R Vyavahare -- CTO and Co-Founder
Naren R Vyavahare -- CTO and Co-Founder
Company News
There are no news available.